Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth
Idexx Laboratories posted a Q3 EPS of $2.79, beating estimates, though revenue of $975.54 million fell short. Veterinary trends and guidance update key 2024 outlook.
